Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

December 16, 2022

https://www.globenewswire.com/news-release/2022/12/16/2575441/15991/en/Amicus-Therapeutics-Receives-Positive-CHMP-Opinion-for-Pombiliti-cipaglucosidase-alfa-for-Late-Onset-Pompe-Disease.html

        CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data

CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Naïve Adults Living with Late-Onset Pompe Disease

Read more at globenewswire.com

Related news for (FOLD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.